Repligen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Repligen and other ETFs, options, and stocks.

About RGEN

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. 

CEO
Olivier Dominique Loeillot
CEOOlivier Dominique Loeillot
Employees
1,778
Employees1,778
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
1981
Founded1981
Employees
1,778
Employees1,778

RGEN Key Statistics

Market cap
9.41B
Market cap9.41B
Price-Earnings ratio
6.45K
Price-Earnings ratio6.45K
Dividend yield
Dividend yield
Average volume
530.48K
Average volume530.48K
High today
$167.08
High today$167.08
Low today
$165.17
Low today$165.17
Open price
$166.41
Open price$166.41
Volume
26.98K
Volume26.98K
52 Week high
$182.52
52 Week high$182.52
52 Week low
$102.97
52 Week low$102.97

Stock Snapshot

The current Repligen(RGEN) stock price is $167.08, with a market capitalization of 9.41B. The stock trades at a price-to-earnings (P/E) ratio of 6448.64.

During the trading session on 2025-12-31, Repligen(RGEN) shares reached a daily high of $167.08 and a low of $165.17. At a current price of $167.08, the stock is +1.2% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 26.98K, compared to an average daily volume of 530.48K.

Over the past 52 weeks, Repligen(RGEN) stock has traded between a high of $182.52 and a low of $102.97.

Over the past 52 weeks, Repligen(RGEN) stock has traded between a high of $182.52 and a low of $102.97.

RGEN News

Simply Wall St 7d
Is Repligen Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins?

In December 2025, Repligen Corporation launched three new high-performance chromatography resins, AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8, and HiPer™ QA, bui...

Is Repligen Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins?

Analyst ratings

74%

of 23 ratings
Buy
73.9%
Hold
26.1%
Sell
0%

People also own

Based on the portfolios of people who own RGEN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.